Objectives: Acute kidney injury (AKI) and acute kidney disease (AKD) are a continuum on a disease spectrum and frequently progress to chronic kidney disease. Benefits of nephrologist subspecialty care during the AKD period after AKI are uncertain.
Methods: Patients with AKI requiring dialysis who subsequently became dialysis independent and survived for at least 90 days, defined as the AKD period, were identified from the Taiwanese population's health insurance database. Cox proportional hazard models using death as the competing risk before and after propensity-score matching were applied to evaluate various endpoints.
Results: Among a total of 20 260 patients with AKI requiring dialysis who became dialysis independent, only 7550 (37.3%) patients were followed up with by a nephrologist (F/U group) during the AKD period. During a mean 4.04 ± 3.56 years of follow-up, the patients in the F/U group were more often administered statin, antihypertensives, angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), diuretics, antiplatelet agents, and antidiabetic agents. The patients in the F/U group had a lower mortality rate (hazard ratio [HR] = 0.87, P < .001) and were less likely to have major adverse cardiovascular events (MACE) (subdistribution HR [sHR] = 0.85, P < .001), congestive heart failure (CHF) (sHR = 0.81, P < .001), and severe sepsis (sHR = 0.88, P = .008) according to the Cox proportional model after adjusting for mortality as a competing risk. During the AKD period, an increase in the frequency of nephrology visits was associated with improved outcomes.
Conclusions: In this population-based cohort, even after weaning off acute dialysis, only a minority of patients visited a nephrologist during the AKD period. We showed that nephrology follow-up is associated with a decrease in MACE, CHF exacerbations, and sepsis, as well as lower mortality; thus it may improve outcomes in patients with AKD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jval.2020.01.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acute kidney disease and postoperative glycemia variability in patients undergoing cardiac surgery: A multicenter cohort analysis of 8,090 patients.
J Clin Anesth
January 2025
School of International Business, China Pharmaceutical University, Jiangsu, China. Electronic address:
Article Synopsis
- The study investigates the link between postoperative glycemic variability (GV) and the risk of acute kidney disease (AKD) in cardiac surgery patients, a topic not previously explored.
- It involved a retrospective analysis of over 8,000 patients, measuring seven-day postoperative GV using various metrics and examining AKD occurrences between 8 to 90 days after surgery.
- Results showed that higher levels of GV were associated with an increased risk of AKD, particularly persistent AKD, and the study established specific GV thresholds to help assess this risk in clinical settings.
Enhanced Outcomes in Type 2 Diabetes Patients with Acute Kidney Disease Through Thiazolidinedione.
J Clin Endocrinol Metab
November 2024
Primary Aldosteronism Center, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Context: Patients with diabetes are prone to acute kidney injury with the potential transition to chronic kidney disease. Few studies have investigated the role of thiazolidinedione (TZD) in these patients under acute kidney disease (AKD) phase.
Objective: We sought to examine whether using TZD during AKD could reduce the risk of future major adverse outcomes.
Acute kidney disease in mice is associated with early cardiovascular dysfunction.
Ren Fail
December 2024
MP3CV laboratory, UR UPJV 7517, University of Picardy Jules Verne, Amiens, France.
Article Synopsis
- Acute kidney injury (AKI) can progress to acute kidney disease (AKD) and potentially to chronic kidney disease (CKD), creating significant health risks, including cardiovascular complications.
- In a mouse study, researchers found that kidney injury resulted in early heart and blood vessel dysfunction, marked by specific changes in protein expression and increased levels of harmful toxins over time.
- The findings emphasize the importance of understanding the early effects of AKD on cardiovascular health to find ways to prevent future heart issues.
Drug-Associated Acute Kidney Disease: Data From a World Pharmacovigilance Database.
Cureus
July 2024
Health and Technology Research Center, Instituto Politécnico de Lisboa, Lisboa, PRT.
Background Drugs are a frequent cause of nephrotoxicity, especially in the context of acute kidney disease (AKD), with a significant number of cases being drug-associated. The WHO's VigiBase is a powerful tool for identifying drugs described and associated with the development of AKD. Methods We retrieved data from the period 1968 to 2022 regarding notifications of adverse drug reactions (ADR).
View Article and Find Full Text PDFUnveiling the enigma of acute kidney disease: predicting prognosis, exploring interventions, and embracing a multidisciplinary approach.
Kidney Res Clin Pract
July 2024
Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Article Synopsis
- * A structured approach called "KAMPS" focuses on monitoring kidney function, medication management, and patient advocacy to improve care for AKD patients, supported by a multidisciplinary team of healthcare professionals.
- * Although research on AKD is limited, potential treatments like ACE inhibitors and SGLT2 inhibitors show promise, highlighting the need for further studies to enhance prognosis and outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!